甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析

Analysis of clinical adverse reactions of apatinib for the treatment of malignant tumors

抗血管生成在恶性肿瘤治疗中的作用日益突出,其在转化、维持治疗过程中都发挥重要作用。我国自主研发的抗血管生成靶向药甲磺酸阿帕替尼(apatinib,YN968D1)已批准用于晚期胃腺癌或胃-食管结合部腺癌的三线及三线以上的治疗,并在多个实体肿瘤中探索应用。随着对阿帕替尼研究的深入,其安全性问题受到广泛关注。本文重点介绍了阿帕替尼在临床应用中常见的不良反应,综合分析了现有的临床数据,对比了阿帕替尼与其他常用抗血管生成药物不良反应的优劣,以期帮助临床医生更好地把握该药的安全性,从而为患者提供更加安全、有效的治疗。

Antiangiogenic targeted therapy plays an important role in the treatment of malignant tumors, especially in the process of antitumor treatment including transformation stage, late stage, and maintenance stage. Apatinib （YN968D1） is a self-developed antiangiogenic targeted agent that was approved and launched for third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma. Moreover, the use of apatinib for other multiple solid tumors has been investigated. With an increase in the number of clinical studies on apatinib, concerns have been raised about its safety. Hence, we highlight the common adverse reactions of apatinib in clinical application and the incidences of various adverse events in different tumor treatments. We provide a comprehensive analysis of available clinical data and compare the advantages and disadvantages of apatinib with other common antiangiogenic drugs regarding their adverse reactions. Overall, these results will help to provide a better understanding of the safety of this medicine in the hope of helping physicians to provide patients with a safe and effective treatment.